MedPath

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Phase 2
Withdrawn
Conditions
Endometrial Cancer
Registration Number
NCT00003821
Lead Sponsor
Genzyme, a Sanofi Company
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory or recurrent endometrial cancer.

Detailed Description

OBJECTIVES: I. Estimate the antitumor activity of aminopterin in patients with persistent, recurrent, or refractory endometrial carcinoma who have failed prior first line cytotoxic chemotherapy. II. Determine the quantitative and qualitative toxic effects of aminopterin in this patient population. III. Determine the overall patient survival and time to progression of these patients. IV. Assess the pharmacokinetic profile of these patients.

OUTLINE: Patients receive oral aminopterin every 12 hours twice weekly. Treatment continues for up to 15 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until death.

PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Division of Gynecologic Oncology

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

East Carolina University School of Medicine

πŸ‡ΊπŸ‡Έ

Greenville, North Carolina, United States

Gynecologic Oncologists of NE Ohio

πŸ‡ΊπŸ‡Έ

Akron, Ohio, United States

Simmons Cancer Center - Dallas

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Texas Oncology, P.A.

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

University of Wisconsin Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Madison, Wisconsin, United States

Division of Gynecologic Oncology
πŸ‡ΊπŸ‡ΈSaint Louis, Missouri, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.